Equities

Human Metabolome Technologies Inc

6090:TYO

Human Metabolome Technologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)619.00
  • Today's Change-1.00 / -0.16%
  • Shares traded5.20k
  • 1 Year change-15.78%
  • Beta1.3310
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments1,7891,6571,505
Total Receivables, Net228130158
Total Inventory372643
Prepaid expenses------
Other current assets, total423536
Total current assets2,0961,8481,742
Property, plant & equipment, net332271243
Goodwill, net------
Intangibles, net17226.11
Long term investments7.007.007.00
Note receivable - long term------
Other long term assets5.196.985.73
Total assets2,6032,2912,069
LIABILITIES
Accounts payable15--0.12
Accrued expenses868377
Notes payable/short-term debt200200200
Current portion long-term debt/capital leases15139.86
Other current liabilities, total316196259
Total current liabilities633493546
Total long term debt111323
Total debt226227233
Deferred income tax------
Minority interest------
Other liabilities, total131313
Total liabilities657519582
SHAREHOLDERS EQUITY
Common stock1,4881,4851,482
Additional paid-in capital6.123.061,470
Retained earnings (accumulated deficit)471308(1444)
Treasury stock - common(0.17)(0.17)(0.14)
Unrealized gain (loss)------
Other equity, total(18)(23)(21)
Total equity1,9471,7721,487
Total liabilities & shareholders' equity2,6032,2912,069
Total common shares outstanding5.925.915.90
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.